title: Immunohistochemical expression of ubiquitin and telomerase in cervical cancer.
abstract: Ubiquitin and telomerase immunohistochemical expression patterns in cervical cancer were compared with normal cervical tissue samples. Eighty-one cervical cancer cases and 22 normal exo-endocervical tissue were examined with polyclonal antibody for ubiquitin and 44G12 clone for telomerase using tissue microarrays. The results were interpreted using a semiquantitative scale The average age of patients was 50.67 years. The most frequent histological types were moderately differentiated epidermoid carcinoma (43.5%), according to the degree of differentiation, and endocervical adenocarcinoma (42.1%). Immunohistochemical findings were as follows: 98.7% of cervical cancers showed immunoexpression for ubiquitin and 52.6% for telomerase. Statistically significant differences were found in tumor immunoreactivity when compared with control tissue (p < 0.0007) for both biomarkers. There was no significant difference in biomarker expression at different histological types of tumors, although telomerase was less expressed in endocervical adenocarcinoma. Our findings confirm that abnormal immunoexpression pattern of ubiquitin and telomerase is common in HPV-positive cervical cancer, indicating the existence of an intense degradation of proteins, subsequent cellular immortalization and maintenance of the malignant phenotype.
authors.affiliation: Exfoliative Cytology, Faculty of Pharmaceutics and Analytical Biosciences, University of Los Andes, Mérida, Venezuela. tmorelva@ula.ve
authors.forename: Toro de Méndez
authors.initials: Tde M
authors.lastname: Morelva
authors.forename: Llombart Bosch
authors.initials: LB
authors.lastname: Antonio
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002584:Cervix Uteri / Q000737:chemistry; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D027383:Papillomaviridae / Q000302:isolation & purification; D019098:Telomerase / Q000032:analysis*; D046888:Tissue Array Analysis; D025801:Ubiquitin / Q000032:analysis*; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000821:virology
chemical_list: D014408:Biomarkers, Tumor; D025801:Ubiquitin; D019098:Telomerase
references.citation: Invest Clin. 2005 Sep;46(3):255-63
references.pmid: 16152781
references.citation: Diagn Cytopathol. 2006 Nov;34(11):739-48
references.pmid: 17041957
references.citation: J Immunol. 2001 Apr 15;166(8):4826-30
references.pmid: 11290757
references.citation: Oncogene. 2002 Jan 21;21(4):664-73
references.pmid: 11850794
references.citation: Semin Cancer Biol. 2003 Feb;13(1):59-67
references.pmid: 12507557
references.citation: Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2563-7
references.pmid: 7708685
references.citation: Oncogene. 2003 Aug 11;22(33):5201-7
references.pmid: 12910257
references.citation: J Biol Chem. 1997 Nov 28;272(48):30135-40
references.pmid: 9374493
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8211-6
references.pmid: 12821782
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Pharmacol Ther. 1998 Jun;78(3):129-39
references.pmid: 9690814
references.citation: Br J Cancer. 2007 Apr 10;96(7):1020-4
references.pmid: 17353922
references.citation: EMBO J. 2005 Oct 5;24(19):3353-9
references.pmid: 16148945
references.citation: Histochem Cell Biol. 2004 May;121(5):391-7
references.pmid: 15138842
references.citation: Am J Pathol. 1997 Jul;151(1):25-31
references.pmid: 9212727
references.citation: FASEB J. 1997 Nov;11(13):1067-75
references.pmid: 9367342
references.citation: J Virol. 2001 Aug;75(15):7198-201
references.pmid: 11435602
references.citation: Oncol Rep. 2002 Jan-Feb;9(1):43-9
references.pmid: 11748453
references.citation: Eur J Cancer. 1997 Apr;33(5):787-91
references.pmid: 9282118
references.citation: N Engl J Med. 1996 Dec 19;335(25):1897-905
references.pmid: 8948566
references.citation: J Virol. 2000 Jul;74(14):6408-17
references.pmid: 10864652
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23
references.pmid: 11158620
references.citation: Gynecol Oncol. 1998 Feb;68(2):145-9
references.pmid: 9514809
references.citation: J Mol Med (Berl). 1997 Jan;75(1):5-17
references.pmid: 9020379
references.citation: Cancer Res. 1996 Oct 15;56(20):4620-4
references.pmid: 8840974
references.citation: Chin Med J (Engl). 2004 Feb;117(2):202-6
references.pmid: 14975203
references.citation: J Natl Cancer Inst. 2000 May 3;92(9):690-8
references.pmid: 10793105
references.citation: Hum Pathol. 2004 Apr;35(4):396-402
references.pmid: 15116318
references.citation: J Virol. 2001 May;75(9):4467-72
references.pmid: 11287602
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: Am J Clin Pathol. 1998 Feb;109(2):153-62
references.pmid: 9583886
references.citation: Zentralbl Gynakol. 2001 Apr;123(4):186-91
references.pmid: 11370525
references.citation: J Virol. 2001 Aug;75(16):7583-91
references.pmid: 11462030
references.citation: J Clin Pathol. 2005 Sep;58(9):911-4
references.pmid: 16126869
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51
references.pmid: 16950017
references.citation: Yonsei Med J. 2005 Oct 31;46(5):597-613
references.pmid: 16259056
references.citation: J Virol. 2001 Jun;75(12):5559-66
references.pmid: 11356963
references.citation: J Clin Pathol. 2003 Jan;56(1):31-5
references.pmid: 12499429
references.citation: Am J Pathol. 2003 Sep;163(3):859-67
references.pmid: 12937127
references.citation: Cancer. 1998 Apr 1;82(7):1319-27
references.pmid: 9529024
references.citation: Cancer Res. 1998 Apr 1;58(7):1558-61
references.pmid: 9537264